Michael Rivner, MD
Clinical Neurophysiology · Macon, GANPI 1669582649
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $251,789 of the $299,935 with a category attached, or 83.9%. 31 manufacturers reported payments, led by AstraZeneca at 38.2% of the total.
Across 488 payments — averaging $614.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$114K
- Argenx US, Inc.$78K
- UCB, Inc.$67K
- AbbVie$19K
- Johnson & Johnson$18K
- UCB SA$2K
- plus $1K from 25 others
Across 119 payments — averaging $6359.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$386K
- Argenx US, Inc.$119K
- Janssen Research & Development, LLC$78K
- Orion Corporation$70K
- UCB GmbH$36K
- AstraZeneca$30K
- plus $39K from 6 others
What the payments were for
- Consulting fees$7,2202%
- Speaking & faculty fees$251,78984%
- Travel & lodging$32,81511%
- Food & beverage$8,0383%
- Education$740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 138 | $114,459 |
| Argenx US, Inc. | 76 | $78,005 |
| UCB, Inc. | 77 | $67,408 |
| AbbVie(2 entities) | 98 | $18,665 |
| Johnson & Johnson | 20 | $18,266 |
| UCB SA | 13 | $1,938 |
| Amgen | 8 | $153 |
| Pfizer | 7 | $149 |
| Tanabe Pharma America, Inc. | 6 | $109 |
| Sunovion Pharmaceuticals Inc. | 14 | $103 |
| Ventec Life Systems, Inc. | 1 | $87 |
| Teva Pharmaceuticals USA, Inc. | 4 | $81 |
| Grifols USA, LLC | 3 | $55 |
| SK Life Science, Inc. | 2 | $53 |
| Revance Therapeutics, Inc. | 2 | $45 |
| Jazz Pharmaceuticals Inc. | 2 | $44 |
| Amylyx Pharmaceuticals, Inc. | 1 | $32 |
| Novartis | 2 | $29 |
| Catalyst Pharmaceuticals, Inc. | 2 | $28 |
| Lundbeck LLC | 1 | $27 |
| Averitas Pharma Inc. | 1 | $27 |
| Greenwich Biosciences, Inc. | 1 | $23 |
| Hospira, Inc. | 1 | $22 |
| EDW Pharma, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| GE HealthCare | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $12 |
| Natus Medical Incorporated | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few clinical neurophysiology providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 189 | $2,677,276 |
| Vyvgart HytruloEfgartigimod-Hyaluronidas-Qvfc | 25 | $1,499,328 |
| VyvgartEfgartigimod Alfa-Fcab | 20 | $1,094,176 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 66 | $1,041,375 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 84 | $936,098 |
| SolirisEculizumab | 14 | $719,414 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 17 | $562,644 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 26 | $313,938 |
| TeglutikRiluzole | 11 | $57,244 |
| Riluzole | 89 | $20,484 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $18,084 |
| Pyridostigmine Bromide | 82 | $10,395 |
| Baclofen | 90 | $3,976 |
| Gabapentin | 69 | $3,973 |
| Glycopyrrolate | 52 | $3,885 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Argenx US, Inc.Vyvgart Hytrulo, Vyvgart | $78,005 | $2,593,50445 claims |
| Grifols USA, LLCGamunex-C | $55 | $1,041,37566 claims |
| AstraZenecaSoliris | $114,459 | $719,41414 claims |
| Amylyx Pharmaceuticals, Inc.Relyvrio | $32 | $313,93826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Other clinical neurophysiology in Macon
- William RocheMacon$474
- Kashyap PatelStatesboro$199K
- Ashish KabirDalton$83K
- Joseph HormesMarietta$4K
- Sachin KedarAtlanta$3K
- Gregory EsperAtlanta$3K
- Sara Ann Schleicher-DilksGainesville$14
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.